The risk of tuberculosis in transplant candidates and recipients

A TBNET consensus statement

Dragos Bumbacea, Sandra M. Arend, Fusun Eyuboglu, Jay A. Fishman, Delia Goletti, Michael G. Ison, Christine E. Jones, Beate Kampmann, Camille N. Kotton, Christoph Lange, Per Ljungman, Heather Milburn, Michele I Morris, Elmi Muller, Patricia Munõz, Anoma Nellore, Hans L. Rieder, Urban Sester, Nicole Theodoropoulos, Dirk Wagner & 1 others Martina Sester

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Tuberculosis (TB) is a possible complication of solid organ and hematopoietic stem cell transplantation. The identification of candidates for preventive chemotherapy is an effective intervention to protect transplant recipients with latent infection with Mycobacterium tuberculosis from progressing to active disease. The best available proxy for diagnosing latent infection with M. tuberculosis is the identification of an adaptive immune response by the tuberculin skin test or an interferon-γ based ex vivo assay. Risk assessment in transplant recipients for the development of TB depends on, among other factors, the locally expected underlying prevalence of infection with M. tuberculosis in the target population. In areas of high prevalence, preventive chemotherapy for all transplant recipients may be justified without immunodiagnostic testing while in areas of medium and low prevalence, preventive chemotherapy should only be offered to candidates with positive M. tuberculosis-specific immune responses. The diagnosis of TB in transplant recipients can be challenging. Treatment of TB is often difficult due to substantial interactions between anti-TB drugs and immunosuppressive medications. This management guideline summarises current knowledge on the prevention, diagnosis and treatment of TB related to solid organ and hematopoietic stem cell transplantation and provides an expert consensus on questions where scientific evidence is still lacking. Copyright

Original languageEnglish
Pages (from-to)990-1013
Number of pages24
JournalEuropean Respiratory Journal
Volume40
Issue number4
DOIs
StatePublished - Oct 1 2012

Fingerprint

Tuberculosis
Mycobacterium tuberculosis
Hematopoietic Stem Cell Transplantation
Drug Therapy
Infection
Tuberculin Test
Health Services Needs and Demand
Proxy
Adaptive Immunity
Immunosuppressive Agents
Skin Tests
Interferons
Transplant Recipients
Guidelines
Therapeutics
Pharmaceutical Preparations

Keywords

  • Guideline
  • Management
  • Mycobacterium tuberculosis
  • Transplantation
  • Tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Bumbacea, D., Arend, S. M., Eyuboglu, F., Fishman, J. A., Goletti, D., Ison, M. G., ... Sester, M. (2012). The risk of tuberculosis in transplant candidates and recipients: A TBNET consensus statement. European Respiratory Journal, 40(4), 990-1013. https://doi.org/10.1183/09031936.00000712

The risk of tuberculosis in transplant candidates and recipients : A TBNET consensus statement. / Bumbacea, Dragos; Arend, Sandra M.; Eyuboglu, Fusun; Fishman, Jay A.; Goletti, Delia; Ison, Michael G.; Jones, Christine E.; Kampmann, Beate; Kotton, Camille N.; Lange, Christoph; Ljungman, Per; Milburn, Heather; Morris, Michele I; Muller, Elmi; Munõz, Patricia; Nellore, Anoma; Rieder, Hans L.; Sester, Urban; Theodoropoulos, Nicole; Wagner, Dirk; Sester, Martina.

In: European Respiratory Journal, Vol. 40, No. 4, 01.10.2012, p. 990-1013.

Research output: Contribution to journalArticle

Bumbacea, D, Arend, SM, Eyuboglu, F, Fishman, JA, Goletti, D, Ison, MG, Jones, CE, Kampmann, B, Kotton, CN, Lange, C, Ljungman, P, Milburn, H, Morris, MI, Muller, E, Munõz, P, Nellore, A, Rieder, HL, Sester, U, Theodoropoulos, N, Wagner, D & Sester, M 2012, 'The risk of tuberculosis in transplant candidates and recipients: A TBNET consensus statement', European Respiratory Journal, vol. 40, no. 4, pp. 990-1013. https://doi.org/10.1183/09031936.00000712
Bumbacea, Dragos ; Arend, Sandra M. ; Eyuboglu, Fusun ; Fishman, Jay A. ; Goletti, Delia ; Ison, Michael G. ; Jones, Christine E. ; Kampmann, Beate ; Kotton, Camille N. ; Lange, Christoph ; Ljungman, Per ; Milburn, Heather ; Morris, Michele I ; Muller, Elmi ; Munõz, Patricia ; Nellore, Anoma ; Rieder, Hans L. ; Sester, Urban ; Theodoropoulos, Nicole ; Wagner, Dirk ; Sester, Martina. / The risk of tuberculosis in transplant candidates and recipients : A TBNET consensus statement. In: European Respiratory Journal. 2012 ; Vol. 40, No. 4. pp. 990-1013.
@article{3af2f4dbf6ad4dec9af870b818518067,
title = "The risk of tuberculosis in transplant candidates and recipients: A TBNET consensus statement",
abstract = "Tuberculosis (TB) is a possible complication of solid organ and hematopoietic stem cell transplantation. The identification of candidates for preventive chemotherapy is an effective intervention to protect transplant recipients with latent infection with Mycobacterium tuberculosis from progressing to active disease. The best available proxy for diagnosing latent infection with M. tuberculosis is the identification of an adaptive immune response by the tuberculin skin test or an interferon-γ based ex vivo assay. Risk assessment in transplant recipients for the development of TB depends on, among other factors, the locally expected underlying prevalence of infection with M. tuberculosis in the target population. In areas of high prevalence, preventive chemotherapy for all transplant recipients may be justified without immunodiagnostic testing while in areas of medium and low prevalence, preventive chemotherapy should only be offered to candidates with positive M. tuberculosis-specific immune responses. The diagnosis of TB in transplant recipients can be challenging. Treatment of TB is often difficult due to substantial interactions between anti-TB drugs and immunosuppressive medications. This management guideline summarises current knowledge on the prevention, diagnosis and treatment of TB related to solid organ and hematopoietic stem cell transplantation and provides an expert consensus on questions where scientific evidence is still lacking. Copyright",
keywords = "Guideline, Management, Mycobacterium tuberculosis, Transplantation, Tuberculosis",
author = "Dragos Bumbacea and Arend, {Sandra M.} and Fusun Eyuboglu and Fishman, {Jay A.} and Delia Goletti and Ison, {Michael G.} and Jones, {Christine E.} and Beate Kampmann and Kotton, {Camille N.} and Christoph Lange and Per Ljungman and Heather Milburn and Morris, {Michele I} and Elmi Muller and Patricia Mun{\~o}z and Anoma Nellore and Rieder, {Hans L.} and Urban Sester and Nicole Theodoropoulos and Dirk Wagner and Martina Sester",
year = "2012",
month = "10",
day = "1",
doi = "10.1183/09031936.00000712",
language = "English",
volume = "40",
pages = "990--1013",
journal = "Acta tuberculosea Scandinavica",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "4",

}

TY - JOUR

T1 - The risk of tuberculosis in transplant candidates and recipients

T2 - A TBNET consensus statement

AU - Bumbacea, Dragos

AU - Arend, Sandra M.

AU - Eyuboglu, Fusun

AU - Fishman, Jay A.

AU - Goletti, Delia

AU - Ison, Michael G.

AU - Jones, Christine E.

AU - Kampmann, Beate

AU - Kotton, Camille N.

AU - Lange, Christoph

AU - Ljungman, Per

AU - Milburn, Heather

AU - Morris, Michele I

AU - Muller, Elmi

AU - Munõz, Patricia

AU - Nellore, Anoma

AU - Rieder, Hans L.

AU - Sester, Urban

AU - Theodoropoulos, Nicole

AU - Wagner, Dirk

AU - Sester, Martina

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Tuberculosis (TB) is a possible complication of solid organ and hematopoietic stem cell transplantation. The identification of candidates for preventive chemotherapy is an effective intervention to protect transplant recipients with latent infection with Mycobacterium tuberculosis from progressing to active disease. The best available proxy for diagnosing latent infection with M. tuberculosis is the identification of an adaptive immune response by the tuberculin skin test or an interferon-γ based ex vivo assay. Risk assessment in transplant recipients for the development of TB depends on, among other factors, the locally expected underlying prevalence of infection with M. tuberculosis in the target population. In areas of high prevalence, preventive chemotherapy for all transplant recipients may be justified without immunodiagnostic testing while in areas of medium and low prevalence, preventive chemotherapy should only be offered to candidates with positive M. tuberculosis-specific immune responses. The diagnosis of TB in transplant recipients can be challenging. Treatment of TB is often difficult due to substantial interactions between anti-TB drugs and immunosuppressive medications. This management guideline summarises current knowledge on the prevention, diagnosis and treatment of TB related to solid organ and hematopoietic stem cell transplantation and provides an expert consensus on questions where scientific evidence is still lacking. Copyright

AB - Tuberculosis (TB) is a possible complication of solid organ and hematopoietic stem cell transplantation. The identification of candidates for preventive chemotherapy is an effective intervention to protect transplant recipients with latent infection with Mycobacterium tuberculosis from progressing to active disease. The best available proxy for diagnosing latent infection with M. tuberculosis is the identification of an adaptive immune response by the tuberculin skin test or an interferon-γ based ex vivo assay. Risk assessment in transplant recipients for the development of TB depends on, among other factors, the locally expected underlying prevalence of infection with M. tuberculosis in the target population. In areas of high prevalence, preventive chemotherapy for all transplant recipients may be justified without immunodiagnostic testing while in areas of medium and low prevalence, preventive chemotherapy should only be offered to candidates with positive M. tuberculosis-specific immune responses. The diagnosis of TB in transplant recipients can be challenging. Treatment of TB is often difficult due to substantial interactions between anti-TB drugs and immunosuppressive medications. This management guideline summarises current knowledge on the prevention, diagnosis and treatment of TB related to solid organ and hematopoietic stem cell transplantation and provides an expert consensus on questions where scientific evidence is still lacking. Copyright

KW - Guideline

KW - Management

KW - Mycobacterium tuberculosis

KW - Transplantation

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84867117821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867117821&partnerID=8YFLogxK

U2 - 10.1183/09031936.00000712

DO - 10.1183/09031936.00000712

M3 - Article

VL - 40

SP - 990

EP - 1013

JO - Acta tuberculosea Scandinavica

JF - Acta tuberculosea Scandinavica

SN - 0903-1936

IS - 4

ER -